Depacon

Overview

valproic acid

GABA modulator

• UGT1A4 substrate
• UGT1A9 substrate
• UGT2B7 substrate
• epoxide hydrolase inhibitor
• UGT1A9 inhibitor
• UGT2B7 inhibitor
• UGT2B15 inhibitor
• CYP1A2 inducer, weak
• UGT1A1 inducer
• affected by altered fat absorption
• antiepileptic agent
• antiplatelet effects
• binds to anion exchange resin/polymer
• CNS depression
• hyperammonemia
• myelosuppressive effects

Contraindicated

• amifampridine
Depacon (valproate sodium)

+

amifampridine

1 interaction

Contraindicated

valproic acid + amifampridine

contraindicated if seizure disorder use; otherwise, caution advised: combo may alter seizure control (antagonistic effects, amifampridine may decr. seizure threshold)

• bupropion
Depacon (valproate sodium)

+

bupropion

1 interaction

Contraindicated

valproic acid + bupropion

contraindicated if seizure disorder use; otherwise, consider lower bupropion doses: combo may alter seizure control (antagonistic effects, bupropion may decr. seizure threshold)

• dalfampridine
Depacon (valproate sodium)

+

dalfampridine

1 interaction

Contraindicated

valproic acid + dalfampridine

contraindicated if seizure disorder use; otherwise, caution advised: combo may alter seizure control (antagonistic effects, dalfampridine may decr. seizure threshold)

Avoid/Use Alternative

• acoramidis
Depacon (valproate sodium)

+

acoramidis

1 interaction

Avoid/Use Alternative

valproic acid + acoramidis

avoid combo: combo may decr. acoramidis levels, efficacy (UGT possibly induced)

• butalbital
Depacon (valproate sodium)

+

butalbital

1 interaction

Avoid/Use Alternative

valproic acid + butalbital

avoid combo: combo may decr. valproic acid levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (UGT induced; additive effects)

• cabotegravir
Depacon (valproate sodium)

+

cabotegravir

1 interaction

Avoid/Use Alternative

valproic acid + cabotegravir

consider alternative: combo may decr. cabotegravir levels, efficacy (UGT induced)

• chloramphenicol
Depacon (valproate sodium)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

valproic acid + chloramphenicol

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cladribine oral
Depacon (valproate sodium)

+

cladribine oral

1 interaction

Avoid/Use Alternative

valproic acid + cladribine oral

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• clonidine
Depacon (valproate sodium)

+

clonidine

1 interaction

Avoid/Use Alternative

valproic acid + clonidine

if ADHD use, avoid combo; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• codeine
Depacon (valproate sodium)

+

codeine

1 interaction

Avoid/Use Alternative

valproic acid + codeine

avoid combo if antitussive use; otherwise monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, codeine may decr. seizure threshold)

• deferiprone
Depacon (valproate sodium)

+

deferiprone

1 interaction

Avoid/Use Alternative

valproic acid + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dolutegravir
Depacon (valproate sodium)

+

dolutegravir

1 interaction

Avoid/Use Alternative

valproic acid + dolutegravir

consider alternative: combo may decr. dolutegravir levels, efficacy (UGT induced)

• doxylamine
Depacon (valproate sodium)

+

doxylamine

1 interaction

Avoid/Use Alternative

valproic acid + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting, otherwise caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• enoxaparin
Depacon (valproate sodium)

+

enoxaparin

1 interaction

Avoid/Use Alternative

valproic acid + enoxaparin

use alternative or monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• ertapenem
Depacon (valproate sodium)

+

ertapenem

1 interaction

Avoid/Use Alternative

valproic acid + ertapenem

use alternative or consider supplemental anticonvulsant tx: combo may decr. valproic acid levels, efficacy; may alter seizure control (mechanism unknown, glucuronide hydrolysis of valproic acid possibly inhibited; antagonistic effects, ertapenem may decr. seizure threshold)

• estradiol (contraceptive)
Depacon (valproate sodium)

+

estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

valproic acid + estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after valproic acid tx; monitor valproic acid levels: combo may decr. estradiol levels, contraceptive efficacy; may decr. valproic acid levels, efficacy (hepatic metabolism induced, UGT induced)

• ethanol
Depacon (valproate sodium)

+

ethanol

1 interaction

Avoid/Use Alternative

valproic acid + ethanol

ORAL ETHANOL: avoid combo; IV ETHANOL: use alternative or monitor respiratory rate, bleeding signs/symptoms: combo with oral ethanol or IV ethanol may increase risk of profound CNS and respiratory depression, psychomotor impairment; oral ethanol may increase risk of GI or other bleeding (additive effects)

• ethinyl estradiol (contraceptive)
Depacon (valproate sodium)

+

ethinyl estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

valproic acid + ethinyl estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after valproic acid tx; monitor valproic acid levels: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may decr. valproic acid levels, efficacy (UGT induced, hepatic metabolism induced)

• fexinidazole
Depacon (valproate sodium)

+

fexinidazole

1 interaction

Avoid/Use Alternative

valproic acid + fexinidazole

use alternative or monitor valproic acid levels, CBC: combo may decr. valproic acid levels, efficacy; may incr. risk of myelosuppression (UGT possibly induced; additive effects)

• fondaparinux
Depacon (valproate sodium)

+

fondaparinux

1 interaction

Avoid/Use Alternative

valproic acid + fondaparinux

use alternative or monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• ganciclovir
Depacon (valproate sodium)

+

ganciclovir

1 interaction

Avoid/Use Alternative

valproic acid + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, ganciclovir may decr. seizure threshold)

• ginkgo
Depacon (valproate sodium)

+

ginkgo

1 interaction

Avoid/Use Alternative

valproic acid + ginkgo

avoid consumption of ginkgo seeds; otherwise, monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening; may alter seizure control (additive effects; antagonistic effects, ginkgotoxin may decr. seizure threshold)

• haloperidol
Depacon (valproate sodium)

+

haloperidol

1 interaction

Avoid/Use Alternative

valproic acid + haloperidol

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, haloperidol may decr. seizure threshold)

• hydrocodone
Depacon (valproate sodium)

+

hydrocodone

1 interaction

Avoid/Use Alternative

valproic acid + hydrocodone

avoid combo if antitussive use; otherwise monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, hydrocodone may decr. seizure threshold)

• imipenem
Depacon (valproate sodium)

+

imipenem

1 interaction

Avoid/Use Alternative

valproic acid + imipenem

use alternative or consider supplemental anticonvulsant tx: combo may decr. valproic acid levels, efficacy; may alter seizure control (mechanism unknown, glucuronide hydrolysis of valproic acid possibly inhibited; antagonistic effects, imipenem may decr. seizure threshold)

• isocarboxazid
Depacon (valproate sodium)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

valproic acid + isocarboxazid

use alternative during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, isocarboxazid may decr. seizure threshold)

• kava
Depacon (valproate sodium)

+

kava

1 interaction

Avoid/Use Alternative

valproic acid + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• kratom
Depacon (valproate sodium)

+

kratom

1 interaction

Avoid/Use Alternative

valproic acid + kratom

use alternative or monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, kratom may decr. seizure threshold)

• letermovir
Depacon (valproate sodium)

+

letermovir

1 interaction

Avoid/Use Alternative

valproic acid + letermovir

avoid combo: combo may decr. letermovir levels, efficacy (UGT induced)

• lorazepam
Depacon (valproate sodium)

+

lorazepam

1 interaction

Avoid/Use Alternative

valproic acid + lorazepam

avoid combo w/ lorazepam ER; monitor resp. rate and decr. lorazepam IR or INJ dose 50%: combo may incr. lorazepam levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (UGT inhibited, additive effects)

• meropenem
Depacon (valproate sodium)

+

meropenem

1 interaction

Avoid/Use Alternative

valproic acid + meropenem

use alternative or monitor valproic acid levels; consider supplemental anticonvulsant tx: combo may decr. valproic acid levels, efficacy; may alter seizure control (mechanism unknown, glucuronide hydrolysis of valproic acid possibly inhibited; antagonistic effects, meropenem may decr. seizure threshold)

• metaxalone
Depacon (valproate sodium)

+

metaxalone

1 interaction

Avoid/Use Alternative

valproic acid + metaxalone

use alternative or monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• metoclopramide
Depacon (valproate sodium)

+

metoclopramide

1 interaction

Avoid/Use Alternative

valproic acid + metoclopramide

use alternative: combo may alter seizure control; may incr. risk of CNS depression, psychomotor impairment (antagonistic effects, metoclopramide may decr. seizure threshold; additive effects)

• midazolam
Depacon (valproate sodium)

+

midazolam

1 interaction

Avoid/Use Alternative

valproic acid + midazolam

use alternative or monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• oxybate
Depacon (valproate sodium)

+

oxybate

1 interaction

Avoid/Use Alternative

valproic acid + oxybate

use alternative or monitor resp. rate; decr. oxybate IR dose at least 20%; no adjustment if oxybate ER form: combo may incr. oxybate levels, risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope, other adverse effects (hepatic metabolism possibly inhibited, additive effects)

• phenelzine
Depacon (valproate sodium)

+

phenelzine

1 interaction

Avoid/Use Alternative

valproic acid + phenelzine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, phenelzine may decr. seizure threshold)

• pivmecillinam
Depacon (valproate sodium)

+

pivmecillinam

1 interaction

Avoid/Use Alternative

valproic acid + pivmecillinam

use alternative or monitor hypocarnitinemia s/sx: combo may incr. risk of carnitine depletion (additive effects)

• primaquine
Depacon (valproate sodium)

+

primaquine

1 interaction

Avoid/Use Alternative

valproic acid + primaquine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• promethazine
Depacon (valproate sodium)

+

promethazine

1 interaction

Avoid/Use Alternative

valproic acid + promethazine

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, promethazine may decr. seizure threshold)

• radium Ra 223 dichloride
Depacon (valproate sodium)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

valproic acid + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ropeginterferon alfa-2b
Depacon (valproate sodium)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

valproic acid + ropeginterferon alfa-2b

use alternative or monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression (additive effects)

• sacituzumab govitecan
Depacon (valproate sodium)

+

sacituzumab govitecan

1 interaction

Avoid/Use Alternative

valproic acid + sacituzumab govitecan

avoid combo: combo may decr. SN-38 levels, efficacy; may incr. risk of myelosuppression (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan; additive effects)

• scopolamine
Depacon (valproate sodium)

+

scopolamine

1 interaction

Avoid/Use Alternative

valproic acid + scopolamine

use alternative: combo may increase risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, scopolamine may decrease seizure threshold)

• thalidomide
Depacon (valproate sodium)

+

thalidomide

1 interaction

Avoid/Use Alternative

valproic acid + thalidomide

use alternative or monitor CBC; consider decr. dose of one or both drugs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thalidomide may decr. seizure threshold)

• topiramate
Depacon (valproate sodium)

+

topiramate

1 interaction

Avoid/Use Alternative

valproic acid + topiramate

use alternative or monitor ammonia levels: combo may incr. risk of hyperammonemia, hypothermia, encephalopathy, CNS depression, psychomotor impairment (additive effects)

• tradipitant
Depacon (valproate sodium)

+

tradipitant

1 interaction

Avoid/Use Alternative

valproic acid + tradipitant

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tranylcypromine
Depacon (valproate sodium)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

valproic acid + tranylcypromine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, tranylcypromine may decr. seizure threshold)

• trimethobenzamide
Depacon (valproate sodium)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

valproic acid + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valganciclovir
Depacon (valproate sodium)

+

valganciclovir

1 interaction

Avoid/Use Alternative

valproic acid + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, ganciclovir may decr. seizure threshold)

• valproic acid
Depacon (valproate sodium)

+

valproic acid

1 interaction

Avoid/Use Alternative

valproic acid + valproic acid

avoid combo: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment, other adverse effects (additive effects, duplicate tx)

• zuranolone
Depacon (valproate sodium)

+

zuranolone

1 interaction

Avoid/Use Alternative

valproic acid + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• abemaciclib
Depacon (valproate sodium)

+

abemaciclib

1 interaction

Monitor/Modify Tx

valproic acid + abemaciclib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• abrocitinib
Depacon (valproate sodium)

+

abrocitinib

1 interaction

Monitor/Modify Tx

valproic acid + abrocitinib

monitor platelets, bleeding s/sx, especially during abrocitinib tx initiation or if abrocitinib 200 mg/day: combo may incr. risk of bleeding (additive effects)

• acalabrutinib
Depacon (valproate sodium)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

valproic acid + acalabrutinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

• acetaminophen
Depacon (valproate sodium)

+

acetaminophen

1 interaction

Monitor/Modify Tx

valproic acid + acetaminophen

consider acetaminophen dose adjustment: combo may incr. acetaminophen levels, risk of adverse effects (UGT inhibited)

• ado-trastuzumab emtansine
Depacon (valproate sodium)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

valproic acid + ado-trastuzumab emtansine

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• afamitresgene autoleucel
Depacon (valproate sodium)

+

afamitresgene autoleucel

1 interaction

Monitor/Modify Tx

valproic acid + afamitresgene autoleucel

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• afatinib
Depacon (valproate sodium)

+

afatinib

1 interaction

Monitor/Modify Tx

valproic acid + afatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• albendazole
Depacon (valproate sodium)

+

albendazole

1 interaction

Monitor/Modify Tx

valproic acid + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• aldesleukin
Depacon (valproate sodium)

+

aldesleukin

1 interaction

Monitor/Modify Tx

valproic acid + aldesleukin

monitor CBC; withhold aldesleukin if mod-severe somnolence occurs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aldesleukin may decr. seizure threshold)

• alemtuzumab
Depacon (valproate sodium)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

valproic acid + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• alfentanil
Depacon (valproate sodium)

+

alfentanil

1 interaction

Monitor/Modify Tx

valproic acid + alfentanil

monitor BP, resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension; may alter seizure control (additive effects; antagonistic effects, alfentanil may decr. seizure threshold)

• allopurinol
Depacon (valproate sodium)

+

allopurinol

1 interaction

Monitor/Modify Tx

valproic acid + allopurinol

monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression (additive effects)

• alpha-tocopherol (vitamin E)
Depacon (valproate sodium)

+

alpha-tocopherol (vitamin E)

1 interaction

Monitor/Modify Tx

valproic acid + alpha-tocopherol (vitamin E)

monitor bleeding signs/symptoms, especially with alpha-tocopherol doses >800 units/day: combo may increase risk of bleeding (additive effects)

• alprazolam
Depacon (valproate sodium)

+

alprazolam

1 interaction

Monitor/Modify Tx

valproic acid + alprazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• alprostadil intracavernous
Depacon (valproate sodium)

+

alprostadil intracavernous

1 interaction

Monitor/Modify Tx

valproic acid + alprostadil intracavernous

monitor injection site bleeding signs/symptoms: combo may increase risk of localized bleeding (additive effects)

• alprostadil intravenous
Depacon (valproate sodium)

+

alprostadil intravenous

1 interaction

Monitor/Modify Tx

valproic acid + alprostadil intravenous

monitor bleeding signs/symptoms: combo may increase risk of bleeding (additive effects)

• alteplase
Depacon (valproate sodium)

+

alteplase

1 interaction

Monitor/Modify Tx

valproic acid + alteplase

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• aminophylline
Depacon (valproate sodium)

+

aminophylline

1 interaction

Monitor/Modify Tx

valproic acid + aminophylline

monitor theophylline levels: combo may decr. theophylline levels, efficacy; may alter seizure control (hepatic metabolism induced, aminophylline converted to theophylline; antagonistic effects, theophylline may decr. seizure threshold)

• amitriptyline
Depacon (valproate sodium)

+

amitriptyline

1 interaction

Monitor/Modify Tx

valproic acid + amitriptyline

monitor amitriptyline levels: combo may incr. amitriptyline levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metabolism possibly inhibited, additive effects; antagonistic effects, amitriptyline may decr. seizure threshold)

• anacaulase topical
Depacon (valproate sodium)

+

anacaulase topical

1 interaction

Monitor/Modify Tx

valproic acid + anacaulase topical

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• anagrelide
Depacon (valproate sodium)

+

anagrelide

1 interaction

Monitor/Modify Tx

valproic acid + anagrelide

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• anti-thymocyte globulin
Depacon (valproate sodium)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

valproic acid + anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• antithrombin
Depacon (valproate sodium)

+

antithrombin

1 interaction

Monitor/Modify Tx

valproic acid + antithrombin

monitor bleeding s/sx: combo may incr. risk of bleeding, including severe (additive effects)

• apixaban
Depacon (valproate sodium)

+

apixaban

1 interaction

Monitor/Modify Tx

valproic acid + apixaban

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• argatroban
Depacon (valproate sodium)

+

argatroban

1 interaction

Monitor/Modify Tx

valproic acid + argatroban

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• arsenic trioxide
Depacon (valproate sodium)

+

arsenic trioxide

1 interaction

Monitor/Modify Tx

valproic acid + arsenic trioxide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• asciminib
Depacon (valproate sodium)

+

asciminib

1 interaction

Monitor/Modify Tx

valproic acid + asciminib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• asparaginase
Depacon (valproate sodium)

+

asparaginase

1 interaction

Monitor/Modify Tx

valproic acid + asparaginase

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• aspirin
Depacon (valproate sodium)

+

aspirin

1 interaction

Monitor/Modify Tx

valproic acid + aspirin

monitor bleeding s/sx, valproic acid levels: combo may incr. valproic acid levels, risk of GI or other bleeding (including life-threatening), other adverse effects (additive effects; mechanism unknown)

• atidarsagene autotemcel
Depacon (valproate sodium)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

valproic acid + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• auranofin
Depacon (valproate sodium)

+

auranofin

1 interaction

Monitor/Modify Tx

valproic acid + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• avapritinib
Depacon (valproate sodium)

+

avapritinib

1 interaction

Monitor/Modify Tx

valproic acid + avapritinib

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• axicabtagene ciloleucel
Depacon (valproate sodium)

+

axicabtagene ciloleucel

1 interaction

Monitor/Modify Tx

valproic acid + axicabtagene ciloleucel

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, axicabtagene ciloleucel may decr. seizure threshold)

• axitinib
Depacon (valproate sodium)

+

axitinib

1 interaction

Monitor/Modify Tx

valproic acid + axitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• azacitidine
Depacon (valproate sodium)

+

azacitidine

1 interaction

Monitor/Modify Tx

valproic acid + azacitidine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• azathioprine
Depacon (valproate sodium)

+

azathioprine

1 interaction

Monitor/Modify Tx

valproic acid + azathioprine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baclofen intrathecal
Depacon (valproate sodium)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

valproic acid + baclofen intrathecal

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, baclofen may decr. seizure threshold)

• balsalazide
Depacon (valproate sodium)

+

balsalazide

1 interaction

Monitor/Modify Tx

valproic acid + balsalazide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baricitinib
Depacon (valproate sodium)

+

baricitinib

1 interaction

Monitor/Modify Tx

valproic acid + baricitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• belantamab mafodotin
Depacon (valproate sodium)

+

belantamab mafodotin

1 interaction

Monitor/Modify Tx

valproic acid + belantamab mafodotin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• belinostat
Depacon (valproate sodium)

+

belinostat

1 interaction

Monitor/Modify Tx

valproic acid + belinostat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• bendamustine
Depacon (valproate sodium)

+

bendamustine

1 interaction

Monitor/Modify Tx

valproic acid + bendamustine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benznidazole
Depacon (valproate sodium)

+

benznidazole

1 interaction

Monitor/Modify Tx

valproic acid + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• betibeglogene autotemcel
Depacon (valproate sodium)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

valproic acid + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• bevacizumab
Depacon (valproate sodium)

+

bevacizumab

1 interaction

Monitor/Modify Tx

valproic acid + bevacizumab

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• bexarotene
Depacon (valproate sodium)

+

bexarotene

1 interaction

Monitor/Modify Tx

valproic acid + bexarotene

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• binimetinib
Depacon (valproate sodium)

+

binimetinib

1 interaction

Monitor/Modify Tx

valproic acid + binimetinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• bivalirudin
Depacon (valproate sodium)

+

bivalirudin

1 interaction

Monitor/Modify Tx

valproic acid + bivalirudin

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• blinatumomab
Depacon (valproate sodium)

+

blinatumomab

1 interaction

Monitor/Modify Tx

valproic acid + blinatumomab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• bortezomib
Depacon (valproate sodium)

+

bortezomib

1 interaction

Monitor/Modify Tx

valproic acid + bortezomib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• bosutinib
Depacon (valproate sodium)

+

bosutinib

1 interaction

Monitor/Modify Tx

valproic acid + bosutinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• brentuximab vedotin
Depacon (valproate sodium)

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

valproic acid + brentuximab vedotin

monitor CBC: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• brexucabtagene autoleucel
Depacon (valproate sodium)

+

brexucabtagene autoleucel

1 interaction

Monitor/Modify Tx

valproic acid + brexucabtagene autoleucel

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, brexucabtagene autoleucel may decr. seizure threshold)

• bromelain
Depacon (valproate sodium)

+

bromelain

1 interaction

Monitor/Modify Tx

valproic acid + bromelain

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• bromfenac ophthalmic
Depacon (valproate sodium)

+

bromfenac ophthalmic

1 interaction

Monitor/Modify Tx

valproic acid + bromfenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• buprenorphine
Depacon (valproate sodium)

+

buprenorphine

1 interaction

Monitor/Modify Tx

valproic acid + buprenorphine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, buprenorphine may decr. seizure threshold)

• busulfan
Depacon (valproate sodium)

+

busulfan

1 interaction

Monitor/Modify Tx

valproic acid + busulfan

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, busulfan may decr. seizure threshold)

• butorphanol
Depacon (valproate sodium)

+

butorphanol

1 interaction

Monitor/Modify Tx

valproic acid + butorphanol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, butorphanol may decr. seizure threshold)

• cabazitaxel
Depacon (valproate sodium)

+

cabazitaxel

1 interaction

Monitor/Modify Tx

valproic acid + cabazitaxel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• cabozantinib
Depacon (valproate sodium)

+

cabozantinib

1 interaction

Monitor/Modify Tx

valproic acid + cabozantinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• caffeine citrate
Depacon (valproate sodium)

+

caffeine citrate

1 interaction

Monitor/Modify Tx

valproic acid + caffeine citrate

monitor caffeine levels: combo may decr. caffeine levels, efficacy (hepatic metabolism induced)

• calaspargase
Depacon (valproate sodium)

+

calaspargase

1 interaction

Monitor/Modify Tx

valproic acid + calaspargase

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• cangrelor
Depacon (valproate sodium)

+

cangrelor

1 interaction

Monitor/Modify Tx

valproic acid + cangrelor

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• cannabidiol
Depacon (valproate sodium)

+

cannabidiol

1 interaction

Monitor/Modify Tx

valproic acid + cannabidiol

monitor ALT, AST, total bilirubin, ammonia levels: combo may incr. risk of CNS depression, psychomotor impairment, hepatocellular injury, hyperammonemia (additive effects)

• capecitabine
Depacon (valproate sodium)

+

capecitabine

1 interaction

Monitor/Modify Tx

valproic acid + capecitabine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• caplacizumab
Depacon (valproate sodium)

+

caplacizumab

1 interaction

Monitor/Modify Tx

valproic acid + caplacizumab

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• carbamazepine
Depacon (valproate sodium)

+

carbamazepine

1 interaction

Monitor/Modify Tx

valproic acid + carbamazepine

monitor levels of both drugs: combo may decr. valproic acid levels, efficacy; may incr. carbamazepine active metabolite levels, risk of CNS depression, psychomotor impairment, other adverse effects (UGT induced; epoxide hydrolase inhibited, additive effects)

• carboplatin
Depacon (valproate sodium)

+

carboplatin

1 interaction

Monitor/Modify Tx

valproic acid + carboplatin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• carfilzomib
Depacon (valproate sodium)

+

carfilzomib

1 interaction

Monitor/Modify Tx

valproic acid + carfilzomib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• carglumic acid
Depacon (valproate sodium)

+

carglumic acid

1 interaction

Monitor/Modify Tx

valproic acid + carglumic acid

monitor ammonia levels: combo may decr. carglumic acid efficacy (antagonistic effects)

• carmustine
Depacon (valproate sodium)

+

carmustine

1 interaction

Monitor/Modify Tx

valproic acid + carmustine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• celecoxib
Depacon (valproate sodium)

+

celecoxib

1 interaction

Monitor/Modify Tx

valproic acid + celecoxib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• chlorambucil
Depacon (valproate sodium)

+

chlorambucil

1 interaction

Monitor/Modify Tx

valproic acid + chlorambucil

monitor CBC, consider chlorambucil dose adjustment: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, chlorambucil may decr. seizure threshold)

• chlordiazepoxide
Depacon (valproate sodium)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

valproic acid + chlordiazepoxide

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• chlorpromazine
Depacon (valproate sodium)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

valproic acid + chlorpromazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, chlorpromazine may decr. seizure threshold)

• cholestyramine
Depacon (valproate sodium)

+

cholestyramine

1 interaction

Monitor/Modify Tx

valproic acid + cholestyramine

separate admin. w/ oral valproic acid by 3h: combo may decr. valproic acid levels, efficacy (absorption decreased/delayed)

• cidofovir
Depacon (valproate sodium)

+

cidofovir

1 interaction

Monitor/Modify Tx

valproic acid + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cilostazol
Depacon (valproate sodium)

+

cilostazol

1 interaction

Monitor/Modify Tx

valproic acid + cilostazol

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• ciltacabtagene autoleucel
Depacon (valproate sodium)

+

ciltacabtagene autoleucel

1 interaction

Monitor/Modify Tx

valproic acid + ciltacabtagene autoleucel

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, ciltacabtagene autoleucel may decr. seizure threshold)

• cisplatin
Depacon (valproate sodium)

+

cisplatin

1 interaction

Monitor/Modify Tx

valproic acid + cisplatin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• citalopram
Depacon (valproate sodium)

+

citalopram

1 interaction

Monitor/Modify Tx

valproic acid + citalopram

monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, citalopram may decr. seizure threshold)

• cladribine injection
Depacon (valproate sodium)

+

cladribine injection

1 interaction

Monitor/Modify Tx

valproic acid + cladribine injection

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• clarithromycin
Depacon (valproate sodium)

+

clarithromycin

1 interaction

Monitor/Modify Tx

valproic acid + clarithromycin

monitor valproic acid levels: combo may incr. valproic acid levels, risk of adverse effects (mechanism unknown, hepatic metabolism possibly inhibited)

• clobazam
Depacon (valproate sodium)

+

clobazam

1 interaction

Monitor/Modify Tx

valproic acid + clobazam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clofarabine
Depacon (valproate sodium)

+

clofarabine

1 interaction

Monitor/Modify Tx

valproic acid + clofarabine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• clonazepam
Depacon (valproate sodium)

+

clonazepam

1 interaction

Monitor/Modify Tx

valproic acid + clonazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may incr. risk of absence seizures (additive effects; mechanism unknown)

• clopidogrel
Depacon (valproate sodium)

+

clopidogrel

1 interaction

Monitor/Modify Tx

valproic acid + clopidogrel

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• clorazepate
Depacon (valproate sodium)

+

clorazepate

1 interaction

Monitor/Modify Tx

valproic acid + clorazepate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clozapine
Depacon (valproate sodium)

+

clozapine

1 interaction

Monitor/Modify Tx

valproic acid + clozapine

monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression; may alter seizure control (additive effects; antagonistic effects, clozapine may decr. seizure threshold)

• colchicine
Depacon (valproate sodium)

+

colchicine

1 interaction

Monitor/Modify Tx

valproic acid + colchicine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• collagenase clostridium histolyticum
Depacon (valproate sodium)

+

collagenase clostridium histolyticum

1 interaction

Monitor/Modify Tx

valproic acid + collagenase clostridium histolyticum

monitor injection site bleeding s/sx: combo may incr. risk of localized bleeding, including severe (additive effects)

• copanlisib
Depacon (valproate sodium)

+

copanlisib

1 interaction

Monitor/Modify Tx

valproic acid + copanlisib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• copper histidinate
Depacon (valproate sodium)

+

copper histidinate

1 interaction

Monitor/Modify Tx

valproic acid + copper histidinate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• crizotinib
Depacon (valproate sodium)

+

crizotinib

1 interaction

Monitor/Modify Tx

valproic acid + crizotinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cyclophosphamide
Depacon (valproate sodium)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

valproic acid + cyclophosphamide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cysteamine
Depacon (valproate sodium)

+

cysteamine

1 interaction

Monitor/Modify Tx

valproic acid + cysteamine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding (additive effects)

• cytarabine
Depacon (valproate sodium)

+

cytarabine

1 interaction

Monitor/Modify Tx

valproic acid + cytarabine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dabigatran
Depacon (valproate sodium)

+

dabigatran

1 interaction

Monitor/Modify Tx

valproic acid + dabigatran

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• dacarbazine
Depacon (valproate sodium)

+

dacarbazine

1 interaction

Monitor/Modify Tx

valproic acid + dacarbazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dactinomycin
Depacon (valproate sodium)

+

dactinomycin

1 interaction

Monitor/Modify Tx

valproic acid + dactinomycin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dalteparin
Depacon (valproate sodium)

+

dalteparin

1 interaction

Monitor/Modify Tx

valproic acid + dalteparin

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• danshen
Depacon (valproate sodium)

+

danshen

1 interaction

Monitor/Modify Tx

valproic acid + danshen

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• dapsone
Depacon (valproate sodium)

+

dapsone

1 interaction

Monitor/Modify Tx

valproic acid + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• daratumumab
Depacon (valproate sodium)

+

daratumumab

1 interaction

Monitor/Modify Tx

valproic acid + daratumumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• daridorexant
Depacon (valproate sodium)

+

daridorexant

1 interaction

Monitor/Modify Tx

valproic acid + daridorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dasatinib
Depacon (valproate sodium)

+

dasatinib

1 interaction

Monitor/Modify Tx

valproic acid + dasatinib

monitor bleeding s/sx, CBC: combo may incr. risk of GI or other bleeding (including life-threatening), myelosuppression (additive effects)

• daunorubicin
Depacon (valproate sodium)

+

daunorubicin

1 interaction

Monitor/Modify Tx

valproic acid + daunorubicin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• decitabine
Depacon (valproate sodium)

+

decitabine

1 interaction

Monitor/Modify Tx

valproic acid + decitabine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• deferasirox
Depacon (valproate sodium)

+

deferasirox

1 interaction

Monitor/Modify Tx

valproic acid + deferasirox

monitor serum ferritin levels, bleeding s/sx, CBC: combo may decr. deferasirox levels, efficacy; may incr. risk of GI or other bleeding (including life-threatening), myelosuppression (UGT induced; additive effects)

• defibrotide
Depacon (valproate sodium)

+

defibrotide

1 interaction

Monitor/Modify Tx

valproic acid + defibrotide

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• desflurane
Depacon (valproate sodium)

+

desflurane

1 interaction

Monitor/Modify Tx

valproic acid + desflurane

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• desvenlafaxine
Depacon (valproate sodium)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

valproic acid + desvenlafaxine

monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, desvenlafaxine may decr. seizure threshold)

• deuruxolitinib
Depacon (valproate sodium)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

valproic acid + deuruxolitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, serious infection, GI or other bleeding (additive effects)

• dexmedetomidine
Depacon (valproate sodium)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

valproic acid + dexmedetomidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine injection
Depacon (valproate sodium)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

valproic acid + dexmedetomidine injection

monitor resp. rate, consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• dexrazoxane
Depacon (valproate sodium)

+

dexrazoxane

1 interaction

Monitor/Modify Tx

valproic acid + dexrazoxane

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• diazepam
Depacon (valproate sodium)

+

diazepam

1 interaction

Monitor/Modify Tx

valproic acid + diazepam

monitor resp. rate, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• diclofenac
Depacon (valproate sodium)

+

diclofenac

1 interaction

Monitor/Modify Tx

valproic acid + diclofenac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• diclofenac ophthalmic
Depacon (valproate sodium)

+

diclofenac ophthalmic

1 interaction

Monitor/Modify Tx

valproic acid + diclofenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• diclofenac topical
Depacon (valproate sodium)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

valproic acid + diclofenac topical

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• diflunisal
Depacon (valproate sodium)

+

diflunisal

1 interaction

Monitor/Modify Tx

valproic acid + diflunisal

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• dihydrocodeine
Depacon (valproate sodium)

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

valproic acid + dihydrocodeine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, dihydrocodeine may decr. seizure threshold)

• dimethyl fumarate
Depacon (valproate sodium)

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

valproic acid + dimethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• dinutuximab
Depacon (valproate sodium)

+

dinutuximab

1 interaction

Monitor/Modify Tx

valproic acid + dinutuximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• diosmin
Depacon (valproate sodium)

+

diosmin

1 interaction

Monitor/Modify Tx

valproic acid + diosmin

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• dipyridamole
Depacon (valproate sodium)

+

dipyridamole

1 interaction

Monitor/Modify Tx

valproic acid + dipyridamole

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• diroximel fumarate
Depacon (valproate sodium)

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

valproic acid + diroximel fumarate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• docetaxel
Depacon (valproate sodium)

+

docetaxel

1 interaction

Monitor/Modify Tx

valproic acid + docetaxel

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dostarlimab
Depacon (valproate sodium)

+

dostarlimab

1 interaction

Monitor/Modify Tx

valproic acid + dostarlimab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• doxorubicin
Depacon (valproate sodium)

+

doxorubicin

1 interaction

Monitor/Modify Tx

valproic acid + doxorubicin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• droperidol
Depacon (valproate sodium)

+

droperidol

1 interaction

Monitor/Modify Tx

valproic acid + droperidol

decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• duloxetine
Depacon (valproate sodium)

+

duloxetine

1 interaction

Monitor/Modify Tx

valproic acid + duloxetine

monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, duloxetine may decr. seizure threshold)

• duvelisib
Depacon (valproate sodium)

+

duvelisib

1 interaction

Monitor/Modify Tx

valproic acid + duvelisib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• edoxaban
Depacon (valproate sodium)

+

edoxaban

1 interaction

Monitor/Modify Tx

valproic acid + edoxaban

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• eflornithine
Depacon (valproate sodium)

+

eflornithine

1 interaction

Monitor/Modify Tx

valproic acid + eflornithine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• elivaldogene autotemcel
Depacon (valproate sodium)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

valproic acid + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, elivaldogene autotemcel may decr. seizure threshold)

• elranatamab
Depacon (valproate sodium)

+

elranatamab

1 interaction

Monitor/Modify Tx

valproic acid + elranatamab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• encorafenib
Depacon (valproate sodium)

+

encorafenib

1 interaction

Monitor/Modify Tx

valproic acid + encorafenib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• enfortumab vedotin
Depacon (valproate sodium)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

valproic acid + enfortumab vedotin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• entrectinib
Depacon (valproate sodium)

+

entrectinib

1 interaction

Monitor/Modify Tx

valproic acid + entrectinib

monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment (additive effects)

• epcoritamab
Depacon (valproate sodium)

+

epcoritamab

1 interaction

Monitor/Modify Tx

valproic acid + epcoritamab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• epirubicin
Depacon (valproate sodium)

+

epirubicin

1 interaction

Monitor/Modify Tx

valproic acid + epirubicin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• epoprostenol
Depacon (valproate sodium)

+

epoprostenol

1 interaction

Monitor/Modify Tx

valproic acid + epoprostenol

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• eptifibatide
Depacon (valproate sodium)

+

eptifibatide

1 interaction

Monitor/Modify Tx

valproic acid + eptifibatide

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• eribulin
Depacon (valproate sodium)

+

eribulin

1 interaction

Monitor/Modify Tx

valproic acid + eribulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• erlotinib
Depacon (valproate sodium)

+

erlotinib

1 interaction

Monitor/Modify Tx

valproic acid + erlotinib

monitor bleeding s/sx: combo may decr. erlotinib levels, efficacy; may incr. risk of GI or other bleeding, including life-threatening (hepatic metabolism induced; additive effects)

• erythromycin
Depacon (valproate sodium)

+

erythromycin

1 interaction

Monitor/Modify Tx

valproic acid + erythromycin

monitor valproic acid levels: combo may incr. valproic acid levels, risk of adverse effects (mechanism unknown, hepatic metabolism possibly inhibited)

• escitalopram
Depacon (valproate sodium)

+

escitalopram

1 interaction

Monitor/Modify Tx

valproic acid + escitalopram

monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, escitalopram may decr. seizure threshold)

• esketamine
Depacon (valproate sodium)

+

esketamine

1 interaction

Monitor/Modify Tx

valproic acid + esketamine

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• estazolam
Depacon (valproate sodium)

+

estazolam

1 interaction

Monitor/Modify Tx

valproic acid + estazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• estradiol (hormone replacement)
Depacon (valproate sodium)

+

estradiol (hormone replacement)

1 interaction

Monitor/Modify Tx

valproic acid + estradiol (hormone replacement)

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• estrogens, conjugated (hormone replacement)
Depacon (valproate sodium)

+

estrogens, conjugated (hormone replacement)

1 interaction

Monitor/Modify Tx

valproic acid + estrogens, conjugated (hormone replacement)

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• estrogens, esterified (hormone replacement)
Depacon (valproate sodium)

+

estrogens, esterified (hormone replacement)

1 interaction

Monitor/Modify Tx

valproic acid + estrogens, esterified (hormone replacement)

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• eszopiclone
Depacon (valproate sodium)

+

eszopiclone

1 interaction

Monitor/Modify Tx

valproic acid + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethanol (in some formulations)
Depacon (valproate sodium)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

valproic acid + ethanol (in some formulations)

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• ethinyl estradiol (hormone replacement)
Depacon (valproate sodium)

+

ethinyl estradiol (hormone replacement)

1 interaction

Monitor/Modify Tx

valproic acid + ethinyl estradiol (hormone replacement)

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• ethosuximide
Depacon (valproate sodium)

+

ethosuximide

1 interaction

Monitor/Modify Tx

valproic acid + ethosuximide

monitor ethosuximide levels: combo may incr. ethosuximide levels, risk of toxicity; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism inhibited; additive effects)

• etodolac
Depacon (valproate sodium)

+

etodolac

1 interaction

Monitor/Modify Tx

valproic acid + etodolac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• etomidate
Depacon (valproate sodium)

+

etomidate

1 interaction

Monitor/Modify Tx

valproic acid + etomidate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• etoposide
Depacon (valproate sodium)

+

etoposide

1 interaction

Monitor/Modify Tx

valproic acid + etoposide

monitor CBC: combo may incr. risk of myelosuppression; may decr. etoposide levels, efficacy (additive effects; mechanism unknown, hepatic metabolism possibly induced)

• etuvetidigene autotemcel
Depacon (valproate sodium)

+

etuvetidigene autotemcel

1 interaction

Monitor/Modify Tx

valproic acid + etuvetidigene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• evening primrose oil
Depacon (valproate sodium)

+

evening primrose oil

1 interaction

Monitor/Modify Tx

valproic acid + evening primrose oil

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• everolimus
Depacon (valproate sodium)

+

everolimus

1 interaction

Monitor/Modify Tx

valproic acid + everolimus

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• exagamglogene autotemcel
Depacon (valproate sodium)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

valproic acid + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fam-trastuzumab deruxtecan
Depacon (valproate sodium)

+

fam-trastuzumab deruxtecan

1 interaction

Monitor/Modify Tx

valproic acid + fam-trastuzumab deruxtecan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fedratinib
Depacon (valproate sodium)

+

fedratinib

1 interaction

Monitor/Modify Tx

valproic acid + fedratinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• felbamate
Depacon (valproate sodium)

+

felbamate

1 interaction

Monitor/Modify Tx

valproic acid + felbamate

monitor valproic acid levels: combo may incr. valproic acid levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• fenoprofen
Depacon (valproate sodium)

+

fenoprofen

1 interaction

Monitor/Modify Tx

valproic acid + fenoprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• fentanyl
Depacon (valproate sodium)

+

fentanyl

1 interaction

Monitor/Modify Tx

valproic acid + fentanyl

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, fentanyl may decr. seizure threshold)

• fenugreek
Depacon (valproate sodium)

+

fenugreek

1 interaction

Monitor/Modify Tx

valproic acid + fenugreek

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• floxuridine
Depacon (valproate sodium)

+

floxuridine

1 interaction

Monitor/Modify Tx

valproic acid + floxuridine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• flucytosine
Depacon (valproate sodium)

+

flucytosine

1 interaction

Monitor/Modify Tx

valproic acid + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fludarabine
Depacon (valproate sodium)

+

fludarabine

1 interaction

Monitor/Modify Tx

valproic acid + fludarabine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluorouracil
Depacon (valproate sodium)

+

fluorouracil

1 interaction

Monitor/Modify Tx

valproic acid + fluorouracil

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluoxetine
Depacon (valproate sodium)

+

fluoxetine

1 interaction

Monitor/Modify Tx

valproic acid + fluoxetine

monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, fluoxetine may decr. seizure threshold)

• fluphenazine
Depacon (valproate sodium)

+

fluphenazine

1 interaction

Monitor/Modify Tx

valproic acid + fluphenazine

monitor CBC; consider decr. dose of one or both drugs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, fluphenazine may decr. seizure threshold)

• flurazepam
Depacon (valproate sodium)

+

flurazepam

1 interaction

Monitor/Modify Tx

valproic acid + flurazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• flurbiprofen
Depacon (valproate sodium)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

valproic acid + flurbiprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• flurbiprofen ophthalmic
Depacon (valproate sodium)

+

flurbiprofen ophthalmic

1 interaction

Monitor/Modify Tx

valproic acid + flurbiprofen ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• fluvoxamine
Depacon (valproate sodium)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

valproic acid + fluvoxamine

monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, fluvoxamine may decr. seizure threshold)

• foscarnet
Depacon (valproate sodium)

+

foscarnet

1 interaction

Monitor/Modify Tx

valproic acid + foscarnet

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, foscarnet may decr. seizure threshold)

• fosfomycin injection
Depacon (valproate sodium)

+

fosfomycin injection

1 interaction

Monitor/Modify Tx

valproic acid + fosfomycin injection

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fosphenytoin
Depacon (valproate sodium)

+

fosphenytoin

1 interaction

Monitor/Modify Tx

valproic acid + fosphenytoin

monitor levels of both drugs, ammonia levels: combo may decr. valproic acid levels, efficacy; may incr. or decr. phenytoin levels, incr. risk of toxicity or decr. efficacy; may incr. risk of CNS depression, psychomotor impairment, hyperammonemia (UGT induced; hepatic metabolism altered; additive effects)

• fostamatinib
Depacon (valproate sodium)

+

fostamatinib

1 interaction

Monitor/Modify Tx

valproic acid + fostamatinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fruquintinib
Depacon (valproate sodium)

+

fruquintinib

1 interaction

Monitor/Modify Tx

valproic acid + fruquintinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• gabapentin
Depacon (valproate sodium)

+

gabapentin

1 interaction

Monitor/Modify Tx

valproic acid + gabapentin

monitor respiratory rate; consider decreasing gabapentin dose: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• gabapentin enacarbil
Depacon (valproate sodium)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

valproic acid + gabapentin enacarbil

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• ganaxolone
Depacon (valproate sodium)

+

ganaxolone

1 interaction

Monitor/Modify Tx

valproic acid + ganaxolone

consider decr. ganaxolone maintenance dose when starting valproic acid: combo may incr. ganaxolone levels, risk of CNS depression, psychomotor impairment, other adverse effects (UGT possibly inhibited, additive effects)

• garlic
Depacon (valproate sodium)

+

garlic

1 interaction

Monitor/Modify Tx

valproic acid + garlic

monitor bleeding s/sx, especially w/ supplemental garlic; dietary intake OK: combo may incr. risk of GI or other bleeding (additive effects)

• gefitinib
Depacon (valproate sodium)

+

gefitinib

1 interaction

Monitor/Modify Tx

valproic acid + gefitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• gemcitabine
Depacon (valproate sodium)

+

gemcitabine

1 interaction

Monitor/Modify Tx

valproic acid + gemcitabine

monitor CBC; risk may be lower w/ intravesical gemcitabine administration: combo may incr. risk of myelosuppression (additive effects)

• gemtuzumab ozogamicin
Depacon (valproate sodium)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

valproic acid + gemtuzumab ozogamicin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

• givinostat
Depacon (valproate sodium)

+

givinostat

1 interaction

Monitor/Modify Tx

valproic acid + givinostat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• glasdegib
Depacon (valproate sodium)

+

glasdegib

1 interaction

Monitor/Modify Tx

valproic acid + glasdegib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• glofitamab
Depacon (valproate sodium)

+

glofitamab

1 interaction

Monitor/Modify Tx

valproic acid + glofitamab

monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression (additive effects)

• glycerol phenylbutyrate
Depacon (valproate sodium)

+

glycerol phenylbutyrate

1 interaction

Monitor/Modify Tx

valproic acid + glycerol phenylbutyrate

monitor ammonia levels: combo may decr. glycerol phenylbutyrate efficacy (antagonistic effects)

• heparin
Depacon (valproate sodium)

+

heparin

1 interaction

Monitor/Modify Tx

valproic acid + heparin

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• hydrocortisone
Depacon (valproate sodium)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

valproic acid + hydrocortisone

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding (additive effects)

• hydromorphone
Depacon (valproate sodium)

+

hydromorphone

1 interaction

Monitor/Modify Tx

valproic acid + hydromorphone

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, hydromorphone may decr. seizure threshold)

• hydroxychloroquine
Depacon (valproate sodium)

+

hydroxychloroquine

1 interaction

Monitor/Modify Tx

valproic acid + hydroxychloroquine

monitor CBC; caution advised if seizure disorder use: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, hydroxychloroquine may decr. seizure threshold)

• hydroxyurea
Depacon (valproate sodium)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

valproic acid + hydroxyurea

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• hydroxyzine
Depacon (valproate sodium)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

valproic acid + hydroxyzine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ibritumomab tiuxetan
Depacon (valproate sodium)

+

ibritumomab tiuxetan

1 interaction

Monitor/Modify Tx

valproic acid + ibritumomab tiuxetan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ibrutinib
Depacon (valproate sodium)

+

ibrutinib

1 interaction

Monitor/Modify Tx

valproic acid + ibrutinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

• ibuprofen
Depacon (valproate sodium)

+

ibuprofen

1 interaction

Monitor/Modify Tx

valproic acid + ibuprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• ibuprofen lysine
Depacon (valproate sodium)

+

ibuprofen lysine

1 interaction

Monitor/Modify Tx

valproic acid + ibuprofen lysine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• icosapent ethyl
Depacon (valproate sodium)

+

icosapent ethyl

1 interaction

Monitor/Modify Tx

valproic acid + icosapent ethyl

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• idarubicin
Depacon (valproate sodium)

+

idarubicin

1 interaction

Monitor/Modify Tx

valproic acid + idarubicin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• idecabtagene vicleucel
Depacon (valproate sodium)

+

idecabtagene vicleucel

1 interaction

Monitor/Modify Tx

valproic acid + idecabtagene vicleucel

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, idecabtagene vicleucel may decr. seizure threshold)

• idelalisib
Depacon (valproate sodium)

+

idelalisib

1 interaction

Monitor/Modify Tx

valproic acid + idelalisib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ifosfamide
Depacon (valproate sodium)

+

ifosfamide

1 interaction

Monitor/Modify Tx

valproic acid + ifosfamide

monitor CBC; D/C one or both drugs if encephalopathy occurs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, ifosfamide may decr. seizure threshold)

• imatinib
Depacon (valproate sodium)

+

imatinib

1 interaction

Monitor/Modify Tx

valproic acid + imatinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding (additive effects)

• imetelstat
Depacon (valproate sodium)

+

imetelstat

1 interaction

Monitor/Modify Tx

valproic acid + imetelstat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• indomethacin
Depacon (valproate sodium)

+

indomethacin

1 interaction

Monitor/Modify Tx

valproic acid + indomethacin

monitor bleeding s/sx: combo may incr. indomethacin levels, risk of GI or other bleeding (including life-threatening), other adverse effects (UGT inhibited, additive effects)

• inotuzumab ozogamicin
Depacon (valproate sodium)

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

valproic acid + inotuzumab ozogamicin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon beta 1a
Depacon (valproate sodium)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

valproic acid + interferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, interferon beta 1a may decr. seizure threshold)

• interferon beta 1b
Depacon (valproate sodium)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

valproic acid + interferon beta 1b

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, interferon beta 1b may decr. seizure threshold)

• interferon gamma 1b
Depacon (valproate sodium)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

valproic acid + interferon gamma 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• irinotecan
Depacon (valproate sodium)

+

irinotecan

1 interaction

Monitor/Modify Tx

valproic acid + irinotecan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• isatuximab
Depacon (valproate sodium)

+

isatuximab

1 interaction

Monitor/Modify Tx

valproic acid + isatuximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• isoflurane
Depacon (valproate sodium)

+

isoflurane

1 interaction

Monitor/Modify Tx

valproic acid + isoflurane

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• isoniazid
Depacon (valproate sodium)

+

isoniazid

1 interaction

Monitor/Modify Tx

valproic acid + isoniazid

monitor valproic acid levels: combo may alter seizure control; may incr. valproic acid levels, risk of adverse effects (antagonistic effects, isoniazid may decr. seizure threshold; mechanism unknown)

• ivosidenib
Depacon (valproate sodium)

+

ivosidenib

1 interaction

Monitor/Modify Tx

valproic acid + ivosidenib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ixabepilone
Depacon (valproate sodium)

+

ixabepilone

1 interaction

Monitor/Modify Tx

valproic acid + ixabepilone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ketamine
Depacon (valproate sodium)

+

ketamine

1 interaction

Monitor/Modify Tx

valproic acid + ketamine

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression (including life-threatening), psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, ketamine may decr. seizure threshold)

• ketoprofen
Depacon (valproate sodium)

+

ketoprofen

1 interaction

Monitor/Modify Tx

valproic acid + ketoprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• ketorolac
Depacon (valproate sodium)

+

ketorolac

1 interaction

Monitor/Modify Tx

valproic acid + ketorolac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening; may alter seizure control (additive effects; antagonistic effects, ketorolac may decr. seizure threshold)

• ketorolac ophthalmic
Depacon (valproate sodium)

+

ketorolac ophthalmic

1 interaction

Monitor/Modify Tx

valproic acid + ketorolac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• lamotrigine
Depacon (valproate sodium)

+

lamotrigine

1 interaction

Monitor/Modify Tx

valproic acid + lamotrigine

titrate slowly, refer to Adult or Peds dosing for guidance: combo may incr. lamotrigine levels, risk of CNS depression, psychomotor impairment, serious skin rash (including life-threating), other adverse effects (UGT inhibited, additive effects)

• leflunomide
Depacon (valproate sodium)

+

leflunomide

1 interaction

Monitor/Modify Tx

valproic acid + leflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lemborexant
Depacon (valproate sodium)

+

lemborexant

1 interaction

Monitor/Modify Tx

valproic acid + lemborexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lenalidomide
Depacon (valproate sodium)

+

lenalidomide

1 interaction

Monitor/Modify Tx

valproic acid + lenalidomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lenvatinib
Depacon (valproate sodium)

+

lenvatinib

1 interaction

Monitor/Modify Tx

valproic acid + lenvatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• levomilnacipran
Depacon (valproate sodium)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

valproic acid + levomilnacipran

monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, levomilnacipran may decr. seizure threshold)

• levorphanol
Depacon (valproate sodium)

+

levorphanol

1 interaction

Monitor/Modify Tx

valproic acid + levorphanol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, levorphanol may decr. seizure threshold)

• levothyroxine
Depacon (valproate sodium)

+

levothyroxine

1 interaction

Monitor/Modify Tx

valproic acid + levothyroxine

monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT induced)

• lifileucel
Depacon (valproate sodium)

+

lifileucel

1 interaction

Monitor/Modify Tx

valproic acid + lifileucel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

• linezolid
Depacon (valproate sodium)

+

linezolid

1 interaction

Monitor/Modify Tx

valproic acid + linezolid

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, linezolid may decr. seizure threshold)

• linvoseltamab
Depacon (valproate sodium)

+

linvoseltamab

1 interaction

Monitor/Modify Tx

valproic acid + linvoseltamab

monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression (additive effects)

• liothyronine
Depacon (valproate sodium)

+

liothyronine

1 interaction

Monitor/Modify Tx

valproic acid + liothyronine

monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT induced)

• lisocabtagene maraleucel
Depacon (valproate sodium)

+

lisocabtagene maraleucel

1 interaction

Monitor/Modify Tx

valproic acid + lisocabtagene maraleucel

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, lisocabtagene maraleucel may decr. seizure threshold)

• lomustine
Depacon (valproate sodium)

+

lomustine

1 interaction

Monitor/Modify Tx

valproic acid + lomustine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lonafarnib
Depacon (valproate sodium)

+

lonafarnib

1 interaction

Monitor/Modify Tx

valproic acid + lonafarnib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• loncastuximab tesirine
Depacon (valproate sodium)

+

loncastuximab tesirine

1 interaction

Monitor/Modify Tx

valproic acid + loncastuximab tesirine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lopinavir/ritonavir
Depacon (valproate sodium)

+

lopinavir/ ritonavir

1 interaction

Monitor/Modify Tx

valproic acid + lopinavir/ ritonavir

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• lovotibeglogene autotemcel
Depacon (valproate sodium)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

valproic acid + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lurbinectedin
Depacon (valproate sodium)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

valproic acid + lurbinectedin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lutetium Lu 177 dotatate
Depacon (valproate sodium)

+

lutetium Lu 177 dotatate

1 interaction

Monitor/Modify Tx

valproic acid + lutetium Lu 177 dotatate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lutetium Lu 177 vipivotide tetraxetan
Depacon (valproate sodium)

+

lutetium Lu 177 vipivotide tetraxetan

1 interaction

Monitor/Modify Tx

valproic acid + lutetium Lu 177 vipivotide tetraxetan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Depacon (valproate sodium)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

valproic acid + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• magnesium salicylate
Depacon (valproate sodium)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

valproic acid + magnesium salicylate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding (additive effects)

• meclofenamate
Depacon (valproate sodium)

+

meclofenamate

1 interaction

Monitor/Modify Tx

valproic acid + meclofenamate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• mefenamic acid
Depacon (valproate sodium)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

valproic acid + mefenamic acid

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• meloxicam
Depacon (valproate sodium)

+

meloxicam

1 interaction

Monitor/Modify Tx

valproic acid + meloxicam

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• melphalan
Depacon (valproate sodium)

+

melphalan

1 interaction

Monitor/Modify Tx

valproic acid + melphalan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• meperidine
Depacon (valproate sodium)

+

meperidine

1 interaction

Monitor/Modify Tx

valproic acid + meperidine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, meperidine may decr. seizure threshold)

• mercaptopurine
Depacon (valproate sodium)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

valproic acid + mercaptopurine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine
Depacon (valproate sodium)

+

mesalamine

1 interaction

Monitor/Modify Tx

valproic acid + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Depacon (valproate sodium)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

valproic acid + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methadone
Depacon (valproate sodium)

+

methadone

1 interaction

Monitor/Modify Tx

valproic acid + methadone

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, methadone may decr. seizure threshold)

• methohexital
Depacon (valproate sodium)

+

methohexital

1 interaction

Monitor/Modify Tx

valproic acid + methohexital

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• methotrexate
Depacon (valproate sodium)

+

methotrexate

1 interaction

Monitor/Modify Tx

valproic acid + methotrexate

monitor CBC, bleeding s/sx, valproic acid levels: combo decr. valproic acid levels, efficacy; may incr. risk of myelosuppression, GI or other bleeding, including life-threatening; may alter seizure control (mechanism unknown; additive effects; antagonistic effects, methotrexate may decr. seizure threshold)

• methyl salicylate topical
Depacon (valproate sodium)

+

methyl salicylate topical

1 interaction

Monitor/Modify Tx

valproic acid + methyl salicylate topical

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects, systemic salicylate absorption may occur from topical use)

• midostaurin
Depacon (valproate sodium)

+

midostaurin

1 interaction

Monitor/Modify Tx

valproic acid + midostaurin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• milnacipran
Depacon (valproate sodium)

+

milnacipran

1 interaction

Monitor/Modify Tx

valproic acid + milnacipran

monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, milnacipran may decr. seizure threshold)

• mirtazapine
Depacon (valproate sodium)

+

mirtazapine

1 interaction

Monitor/Modify Tx

valproic acid + mirtazapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, mirtazapine may decr. seizure threshold)

• mitomycin
Depacon (valproate sodium)

+

mitomycin

1 interaction

Monitor/Modify Tx

valproic acid + mitomycin

monitor CBC; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of myelosuppression (additive effects)

• mitotane
Depacon (valproate sodium)

+

mitotane

1 interaction

Monitor/Modify Tx

valproic acid + mitotane

monitor CBC, bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression, bleeding (additive effects)

• mitoxantrone
Depacon (valproate sodium)

+

mitoxantrone

1 interaction

Monitor/Modify Tx

valproic acid + mitoxantrone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mogamulizumab
Depacon (valproate sodium)

+

mogamulizumab

1 interaction

Monitor/Modify Tx

valproic acid + mogamulizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• momelotinib
Depacon (valproate sodium)

+

momelotinib

1 interaction

Monitor/Modify Tx

valproic acid + momelotinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• monomethyl fumarate
Depacon (valproate sodium)

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

valproic acid + monomethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• morphine
Depacon (valproate sodium)

+

morphine

1 interaction

Monitor/Modify Tx

valproic acid + morphine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, morphine may decr. seizure threshold)

• mosunetuzumab
Depacon (valproate sodium)

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

valproic acid + mosunetuzumab

monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment (additive effects)

• mycophenolate mofetil
Depacon (valproate sodium)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

valproic acid + mycophenolate mofetil

monitor CBC, bleeding s/sx, consider monitoring mycophenolic acid levels: combo may incr. mycophenolic acid levels, risk of serious infection, myelosuppression, GI or other bleeding, CNS depression, psychomotor impairment, other adverse effects (UGT inhibited, additive effects)

• mycophenolic acid
Depacon (valproate sodium)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

valproic acid + mycophenolic acid

monitor CBC, bleeding s/sx: combo may incr. mycophenolic acid levels, risk of serious infection, myelosuppression, GI or other bleeding, other adverse effects (UGT inhibited, additive effects)

• nabumetone
Depacon (valproate sodium)

+

nabumetone

1 interaction

Monitor/Modify Tx

valproic acid + nabumetone

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• nalbuphine
Depacon (valproate sodium)

+

nalbuphine

1 interaction

Monitor/Modify Tx

valproic acid + nalbuphine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, nalbuphine may decr. seizure threshold)

• naproxen
Depacon (valproate sodium)

+

naproxen

1 interaction

Monitor/Modify Tx

valproic acid + naproxen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• nattokinase
Depacon (valproate sodium)

+

nattokinase

1 interaction

Monitor/Modify Tx

valproic acid + nattokinase

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• nelarabine
Depacon (valproate sodium)

+

nelarabine

1 interaction

Monitor/Modify Tx

valproic acid + nelarabine

monitor CBC; withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, nelarabine may decr. seizure threshold)

• nelfinavir
Depacon (valproate sodium)

+

nelfinavir

1 interaction

Monitor/Modify Tx

valproic acid + nelfinavir

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• nepafenac ophthalmic
Depacon (valproate sodium)

+

nepafenac ophthalmic

1 interaction

Monitor/Modify Tx

valproic acid + nepafenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• nevirapine
Depacon (valproate sodium)

+

nevirapine

1 interaction

Monitor/Modify Tx

valproic acid + nevirapine

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• niacin (vitamin B3)
Depacon (valproate sodium)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

valproic acid + niacin (vitamin B3)

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• nilotinib
Depacon (valproate sodium)

+

nilotinib

1 interaction

Monitor/Modify Tx

valproic acid + nilotinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• nintedanib
Depacon (valproate sodium)

+

nintedanib

1 interaction

Monitor/Modify Tx

valproic acid + nintedanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• niraparib
Depacon (valproate sodium)

+

niraparib

1 interaction

Monitor/Modify Tx

valproic acid + niraparib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• nortriptyline
Depacon (valproate sodium)

+

nortriptyline

1 interaction

Monitor/Modify Tx

valproic acid + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metabolism possibly inhibited, additive effects; antagonistic effects, nortriptyline may decr. seizure threshold)

• nusinersen
Depacon (valproate sodium)

+

nusinersen

1 interaction

Monitor/Modify Tx

valproic acid + nusinersen

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• obecabtagene autoleucel
Depacon (valproate sodium)

+

obecabtagene autoleucel

1 interaction

Monitor/Modify Tx

valproic acid + obecabtagene autoleucel

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, obecabtagene autoleucel may decr. seizure threshold)

• obinutuzumab
Depacon (valproate sodium)

+

obinutuzumab

1 interaction

Monitor/Modify Tx

valproic acid + obinutuzumab

monitor CBC, platelets, bleeding s/sx; consider holding valproic acid, especially during first obinutuzumab cycle: combo may incr. risk of myelosuppression, severe bleeding, including life-threatening (additive effects)

• ofatumumab
Depacon (valproate sodium)

+

ofatumumab

1 interaction

Monitor/Modify Tx

valproic acid + ofatumumab

monitor CBC; myelosuppression risk may be lower w/ ofatumumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• olanzapine
Depacon (valproate sodium)

+

olanzapine

1 interaction

Monitor/Modify Tx

valproic acid + olanzapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis; may alter seizure control (additive effects; antagonistic effects, olanzapine may decr. seizure threshold)

• olaparib
Depacon (valproate sodium)

+

olaparib

1 interaction

Monitor/Modify Tx

valproic acid + olaparib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• oliceridine
Depacon (valproate sodium)

+

oliceridine

1 interaction

Monitor/Modify Tx

valproic acid + oliceridine

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension; may alter seizure control (additive effects; antagonistic effects, oliceridine may decr. seizure threshold)

• olsalazine
Depacon (valproate sodium)

+

olsalazine

1 interaction

Monitor/Modify Tx

valproic acid + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• omega-3-acid
Depacon (valproate sodium)

+

omega-3-acid

1 interaction

Monitor/Modify Tx

valproic acid + omega-3-acid

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• opicapone
Depacon (valproate sodium)

+

opicapone

1 interaction

Monitor/Modify Tx

valproic acid + opicapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• opium
Depacon (valproate sodium)

+

opium

1 interaction

Monitor/Modify Tx

valproic acid + opium

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, morphine in opium may decr. seizure threshold)

• oxaliplatin
Depacon (valproate sodium)

+

oxaliplatin

1 interaction

Monitor/Modify Tx

valproic acid + oxaliplatin

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding (additive effects)

• oxaprozin
Depacon (valproate sodium)

+

oxaprozin

1 interaction

Monitor/Modify Tx

valproic acid + oxaprozin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• oxazepam
Depacon (valproate sodium)

+

oxazepam

1 interaction

Monitor/Modify Tx

valproic acid + oxazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• oxybutynin
Depacon (valproate sodium)

+

oxybutynin

1 interaction

Monitor/Modify Tx

valproic acid + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment; somnolence less likely with oxybutynin transdermal patch (additive effects)

• oxycodone
Depacon (valproate sodium)

+

oxycodone

1 interaction

Monitor/Modify Tx

valproic acid + oxycodone

monitor resp. rate; decr. oxycodone start dose by at least 50%, consider decr. valproic acid dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, oxycodone may decr. seizure threshold)

• oxymorphone
Depacon (valproate sodium)

+

oxymorphone

1 interaction

Monitor/Modify Tx

valproic acid + oxymorphone

monitor resp. rate; decr. oxymorphone start dose by at least 50%, consider decr. valproic acid dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, oxymorphone may decr. seizure threshold)

• paclitaxel
Depacon (valproate sodium)

+

paclitaxel

1 interaction

Monitor/Modify Tx

valproic acid + paclitaxel

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pacritinib
Depacon (valproate sodium)

+

pacritinib

1 interaction

Monitor/Modify Tx

valproic acid + pacritinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

• palbociclib
Depacon (valproate sodium)

+

palbociclib

1 interaction

Monitor/Modify Tx

valproic acid + palbociclib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• paroxetine
Depacon (valproate sodium)

+

paroxetine

1 interaction

Monitor/Modify Tx

valproic acid + paroxetine

monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, paroxetine may decr. seizure threshold)

• pazopanib
Depacon (valproate sodium)

+

pazopanib

1 interaction

Monitor/Modify Tx

valproic acid + pazopanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• pegaspargase
Depacon (valproate sodium)

+

pegaspargase

1 interaction

Monitor/Modify Tx

valproic acid + pegaspargase

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• peginterferon alfa 2a
Depacon (valproate sodium)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

valproic acid + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Depacon (valproate sodium)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

valproic acid + peginterferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, peginterferon beta 1a may decr. seizure threshold)

• pemetrexed
Depacon (valproate sodium)

+

pemetrexed

1 interaction

Monitor/Modify Tx

valproic acid + pemetrexed

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• penicillamine
Depacon (valproate sodium)

+

penicillamine

1 interaction

Monitor/Modify Tx

valproic acid + penicillamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• penicillin G
Depacon (valproate sodium)

+

penicillin G

1 interaction

Monitor/Modify Tx

valproic acid + penicillin G

monitor bleeding s/sx, especially w/ large penicillin G doses and/or concomitant renal impairment: combo may incr. risk of bleeding; may alter seizure control (additive effects; antagonistic effects, penicillin G may decr. seizure threshold)

• pentamidine
Depacon (valproate sodium)

+

pentamidine

1 interaction

Monitor/Modify Tx

valproic acid + pentamidine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentazocine
Depacon (valproate sodium)

+

pentazocine

1 interaction

Monitor/Modify Tx

valproic acid + pentazocine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, pentazocine may decr. seizure threshold)

• pentobarbital
Depacon (valproate sodium)

+

pentobarbital

1 interaction

Monitor/Modify Tx

valproic acid + pentobarbital

monitor valproic acid levels, resp. rate: combo may decr. valproic acid levels, efficacy; may incr. pentobarbital levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (UGT induced; hepatic metabolism possibly inhibited, additive effects)

• pentosan polysulfate sodium
Depacon (valproate sodium)

+

pentosan polysulfate sodium

1 interaction

Monitor/Modify Tx

valproic acid + pentosan polysulfate sodium

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• pentostatin
Depacon (valproate sodium)

+

pentostatin

1 interaction

Monitor/Modify Tx

valproic acid + pentostatin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentoxifylline
Depacon (valproate sodium)

+

pentoxifylline

1 interaction

Monitor/Modify Tx

valproic acid + pentoxifylline

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• perphenazine
Depacon (valproate sodium)

+

perphenazine

1 interaction

Monitor/Modify Tx

valproic acid + perphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, perphenazine may decr. seizure threshold)

• phenobarbital
Depacon (valproate sodium)

+

phenobarbital

1 interaction

Monitor/Modify Tx

valproic acid + phenobarbital

monitor levels of both drugs, ECG, resp. rate: combo may incr. phenobarbital levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. valproic acid levels, efficacy (hepatic metabolism possibly inhibited, additive effects; hepatic metabolism possibly induced, UGT possibly induced)

• phenytoin
Depacon (valproate sodium)

+

phenytoin

1 interaction

Monitor/Modify Tx

valproic acid + phenytoin

monitor levels of both drugs, ammonia levels: combo may decr. valproic acid levels, efficacy; may incr. or decr. phenytoin levels, incr. risk of toxicity or decr. efficacy; may incr. risk of CNS depression, psychomotor impairment, hyperammonemia (UGT induced; hepatic metabolism altered; additive effects)

• piperacillin
Depacon (valproate sodium)

+

piperacillin

1 interaction

Monitor/Modify Tx

valproic acid + piperacillin

monitor bleeding s/sx, especially w/ prolonged piperacillin tx and/or concomitant renal impairment: combo may incr. risk of bleeding; may alter seizure control (additive effects; antagonistic effects, piperacillin may decr. seizure threshold)

• piroxicam
Depacon (valproate sodium)

+

piroxicam

1 interaction

Monitor/Modify Tx

valproic acid + piroxicam

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• pirtobrutinib
Depacon (valproate sodium)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

valproic acid + pirtobrutinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• plasminogen, human
Depacon (valproate sodium)

+

plasminogen, human

1 interaction

Monitor/Modify Tx

valproic acid + plasminogen, human

monitor bleeding s/sx, especially during and x4h after plasminogen infusion: combo may incr. risk of GI or other bleeding (additive effects)

• polatuzumab vedotin
Depacon (valproate sodium)

+

polatuzumab vedotin

1 interaction

Monitor/Modify Tx

valproic acid + polatuzumab vedotin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pomalidomide
Depacon (valproate sodium)

+

pomalidomide

1 interaction

Monitor/Modify Tx

valproic acid + pomalidomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ponatinib
Depacon (valproate sodium)

+

ponatinib

1 interaction

Monitor/Modify Tx

valproic acid + ponatinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• porfimer
Depacon (valproate sodium)

+

porfimer

1 interaction

Monitor/Modify Tx

valproic acid + porfimer

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• pralatrexate
Depacon (valproate sodium)

+

pralatrexate

1 interaction

Monitor/Modify Tx

valproic acid + pralatrexate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pralsetinib
Depacon (valproate sodium)

+

pralsetinib

1 interaction

Monitor/Modify Tx

valproic acid + pralsetinib

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• prasugrel
Depacon (valproate sodium)

+

prasugrel

1 interaction

Monitor/Modify Tx

valproic acid + prasugrel

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• pregabalin
Depacon (valproate sodium)

+

pregabalin

1 interaction

Monitor/Modify Tx

valproic acid + pregabalin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• primidone
Depacon (valproate sodium)

+

primidone

1 interaction

Monitor/Modify Tx

valproic acid + primidone

monitor levels, resp. rate: combo may decr. valproic acid levels, efficacy; may incr. primidone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (UGT induced; hepatic metabolism inhibited, additive effects)

• procarbazine
Depacon (valproate sodium)

+

procarbazine

1 interaction

Monitor/Modify Tx

valproic acid + procarbazine

monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, procarbazine may decr. seizure threshold)

• proguanil
Depacon (valproate sodium)

+

proguanil

1 interaction

Monitor/Modify Tx

valproic acid + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• propofol
Depacon (valproate sodium)

+

propofol

1 interaction

Monitor/Modify Tx

valproic acid + propofol

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. propofol levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects; may alter seizure control (UGT inhibited, additive effects; antagonistic effects, propofol may decr. seizure threshold)

• pyrimethamine
Depacon (valproate sodium)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

valproic acid + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, pyrimethamine may decr. seizure threshold)

• quazepam
Depacon (valproate sodium)

+

quazepam

1 interaction

Monitor/Modify Tx

valproic acid + quazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quizartinib
Depacon (valproate sodium)

+

quizartinib

1 interaction

Monitor/Modify Tx

valproic acid + quizartinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ramucirumab
Depacon (valproate sodium)

+

ramucirumab

1 interaction

Monitor/Modify Tx

valproic acid + ramucirumab

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• ranibizumab
Depacon (valproate sodium)

+

ranibizumab

1 interaction

Monitor/Modify Tx

valproic acid + ranibizumab

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• regorafenib
Depacon (valproate sodium)

+

regorafenib

1 interaction

Monitor/Modify Tx

valproic acid + regorafenib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• remibrutinib
Depacon (valproate sodium)

+

remibrutinib

1 interaction

Monitor/Modify Tx

valproic acid + remibrutinib

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• remifentanil
Depacon (valproate sodium)

+

remifentanil

1 interaction

Monitor/Modify Tx

valproic acid + remifentanil

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, remifentanil may decr. seizure threshold)

• remimazolam
Depacon (valproate sodium)

+

remimazolam

1 interaction

Monitor/Modify Tx

valproic acid + remimazolam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• resveratrol
Depacon (valproate sodium)

+

resveratrol

1 interaction

Monitor/Modify Tx

valproic acid + resveratrol

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• reteplase
Depacon (valproate sodium)

+

reteplase

1 interaction

Monitor/Modify Tx

valproic acid + reteplase

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• revakinagene taroretcel
Depacon (valproate sodium)

+

revakinagene taroretcel

1 interaction

Monitor/Modify Tx

valproic acid + revakinagene taroretcel

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ribavirin
Depacon (valproate sodium)

+

ribavirin

1 interaction

Monitor/Modify Tx

valproic acid + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ribociclib
Depacon (valproate sodium)

+

ribociclib

1 interaction

Monitor/Modify Tx

valproic acid + ribociclib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rifabutin
Depacon (valproate sodium)

+

rifabutin

1 interaction

Monitor/Modify Tx

valproic acid + rifabutin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rifampin
Depacon (valproate sodium)

+

rifampin

1 interaction

Monitor/Modify Tx

valproic acid + rifampin

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• ritonavir
Depacon (valproate sodium)

+

ritonavir

1 interaction

Monitor/Modify Tx

valproic acid + ritonavir

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• rituximab
Depacon (valproate sodium)

+

rituximab

1 interaction

Monitor/Modify Tx

valproic acid + rituximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rivaroxaban
Depacon (valproate sodium)

+

rivaroxaban

1 interaction

Monitor/Modify Tx

valproic acid + rivaroxaban

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• romidepsin
Depacon (valproate sodium)

+

romidepsin

1 interaction

Monitor/Modify Tx

valproic acid + romidepsin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rucaparib
Depacon (valproate sodium)

+

rucaparib

1 interaction

Monitor/Modify Tx

valproic acid + rucaparib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rufinamide
Depacon (valproate sodium)

+

rufinamide

1 interaction

Monitor/Modify Tx

valproic acid + rufinamide

start valproate at low dose in pts on rufinamide; start rufinamide <400 mg/day in adult pts or <10 mg/kg/day in peds pts on valproate: combo may incr. rufinamide levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• ruxolitinib
Depacon (valproate sodium)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

valproic acid + ruxolitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ruxolitinib topical
Depacon (valproate sodium)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

valproic acid + ruxolitinib topical

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• salsalate
Depacon (valproate sodium)

+

salsalate

1 interaction

Monitor/Modify Tx

valproic acid + salsalate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• sapropterin
Depacon (valproate sodium)

+

sapropterin

1 interaction

Monitor/Modify Tx

valproic acid + sapropterin

monitor Phe levels: combo may decr. sapropterin efficacy (dihydrofolate reductase inhibited)

• sarilumab
Depacon (valproate sodium)

+

sarilumab

1 interaction

Monitor/Modify Tx

valproic acid + sarilumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• satralizumab
Depacon (valproate sodium)

+

satralizumab

1 interaction

Monitor/Modify Tx

valproic acid + satralizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• saw palmetto
Depacon (valproate sodium)

+

saw palmetto

1 interaction

Monitor/Modify Tx

valproic acid + saw palmetto

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• selinexor
Depacon (valproate sodium)

+

selinexor

1 interaction

Monitor/Modify Tx

valproic acid + selinexor

monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment (additive effects)

• selpercatinib
Depacon (valproate sodium)

+

selpercatinib

1 interaction

Monitor/Modify Tx

valproic acid + selpercatinib

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• selumetinib
Depacon (valproate sodium)

+

selumetinib

1 interaction

Monitor/Modify Tx

valproic acid + selumetinib

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects, antiplatelet and anticoagulant effects augmented by vitamin E content in selumetinib capsules)

• sepiapterin
Depacon (valproate sodium)

+

sepiapterin

1 interaction

Monitor/Modify Tx

valproic acid + sepiapterin

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• sertraline
Depacon (valproate sodium)

+

sertraline

1 interaction

Monitor/Modify Tx

valproic acid + sertraline

monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, sertraline may decr. seizure threshold)

• sevoflurane
Depacon (valproate sodium)

+

sevoflurane

1 interaction

Monitor/Modify Tx

valproic acid + sevoflurane

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, sevoflurane may decr. seizure threshold)

• sirolimus
Depacon (valproate sodium)

+

sirolimus

1 interaction

Monitor/Modify Tx

valproic acid + sirolimus

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sirolimus albumin-bound
Depacon (valproate sodium)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

valproic acid + sirolimus albumin-bound

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

• sodium phenylacetate
Depacon (valproate sodium)

+

sodium phenylacetate

1 interaction

Monitor/Modify Tx

valproic acid + sodium phenylacetate

monitor ammonia levels: combo may decr. sodium phenylacetate efficacy (antagonistic effects)

• sodium phenylbutyrate
Depacon (valproate sodium)

+

sodium phenylbutyrate

1 interaction

Monitor/Modify Tx

valproic acid + sodium phenylbutyrate

monitor ammonia levels: combo may decr. sodium phenylbutyrate efficacy (antagonistic effects)

• sorafenib
Depacon (valproate sodium)

+

sorafenib

1 interaction

Monitor/Modify Tx

valproic acid + sorafenib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• sotatercept
Depacon (valproate sodium)

+

sotatercept

1 interaction

Monitor/Modify Tx

valproic acid + sotatercept

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, including severe (additive effects)

• stiripentol
Depacon (valproate sodium)

+

stiripentol

1 interaction

Monitor/Modify Tx

valproic acid + stiripentol

monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment (additive effects)

• streptozocin
Depacon (valproate sodium)

+

streptozocin

1 interaction

Monitor/Modify Tx

valproic acid + streptozocin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• succimer
Depacon (valproate sodium)

+

succimer

1 interaction

Monitor/Modify Tx

valproic acid + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sufentanil
Depacon (valproate sodium)

+

sufentanil

1 interaction

Monitor/Modify Tx

valproic acid + sufentanil

monitor resp. rate, decr. sufentanil start dose, consider decr. valproic acid dose, use lowest effective doses: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, sufentanil may decr. seizure threshold)

• sulfasalazine
Depacon (valproate sodium)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

valproic acid + sulfasalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulindac
Depacon (valproate sodium)

+

sulindac

1 interaction

Monitor/Modify Tx

valproic acid + sulindac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• sunitinib
Depacon (valproate sodium)

+

sunitinib

1 interaction

Monitor/Modify Tx

valproic acid + sunitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• suvorexant
Depacon (valproate sodium)

+

suvorexant

1 interaction

Monitor/Modify Tx

valproic acid + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tafasitamab
Depacon (valproate sodium)

+

tafasitamab

1 interaction

Monitor/Modify Tx

valproic acid + tafasitamab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tagraxofusp
Depacon (valproate sodium)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

valproic acid + tagraxofusp

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• talazoparib
Depacon (valproate sodium)

+

talazoparib

1 interaction

Monitor/Modify Tx

valproic acid + talazoparib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• talquetamab
Depacon (valproate sodium)

+

talquetamab

1 interaction

Monitor/Modify Tx

valproic acid + talquetamab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tapentadol
Depacon (valproate sodium)

+

tapentadol

1 interaction

Monitor/Modify Tx

valproic acid + tapentadol

monitor respiratory rate, BP; decrease dose of one or both drugs, use lowest effective doses and shortest duration of concomitant treatment: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, tapentadol may decrease seizure threshold)

• tarlatamab
Depacon (valproate sodium)

+

tarlatamab

1 interaction

Monitor/Modify Tx

valproic acid + tarlatamab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tazemetostat
Depacon (valproate sodium)

+

tazemetostat

1 interaction

Monitor/Modify Tx

valproic acid + tazemetostat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• teclistamab
Depacon (valproate sodium)

+

teclistamab

1 interaction

Monitor/Modify Tx

valproic acid + teclistamab

monitor CBC: combo may alter seizure control; may incr. risk of myelosuppression (antagonistic effects, teclistamab may decr. seizure threshold; additive effects)

• telmisartan
Depacon (valproate sodium)

+

telmisartan

1 interaction

Monitor/Modify Tx

valproic acid + telmisartan

monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

• temazepam
Depacon (valproate sodium)

+

temazepam

1 interaction

Monitor/Modify Tx

valproic acid + temazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• temozolomide
Depacon (valproate sodium)

+

temozolomide

1 interaction

Monitor/Modify Tx

valproic acid + temozolomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• temsirolimus
Depacon (valproate sodium)

+

temsirolimus

1 interaction

Monitor/Modify Tx

valproic acid + temsirolimus

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tenecteplase
Depacon (valproate sodium)

+

tenecteplase

1 interaction

Monitor/Modify Tx

valproic acid + tenecteplase

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• teplizumab
Depacon (valproate sodium)

+

teplizumab

1 interaction

Monitor/Modify Tx

valproic acid + teplizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• teriflunomide
Depacon (valproate sodium)

+

teriflunomide

1 interaction

Monitor/Modify Tx

valproic acid + teriflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• theophylline
Depacon (valproate sodium)

+

theophylline

1 interaction

Monitor/Modify Tx

valproic acid + theophylline

monitor theophylline levels: combo may decr. theophylline levels, efficacy; may alter seizure control (hepatic metabolism induced; antagonistic effects, theophylline may decr. seizure threshold)

• thioguanine
Depacon (valproate sodium)

+

thioguanine

1 interaction

Monitor/Modify Tx

valproic acid + thioguanine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• thioridazine
Depacon (valproate sodium)

+

thioridazine

1 interaction

Monitor/Modify Tx

valproic acid + thioridazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thioridazine may decr. seizure threshold)

• thiotepa
Depacon (valproate sodium)

+

thiotepa

1 interaction

Monitor/Modify Tx

valproic acid + thiotepa

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thiotepa may decr. seizure threshold)

• thiothixene
Depacon (valproate sodium)

+

thiothixene

1 interaction

Monitor/Modify Tx

valproic acid + thiothixene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thiothixene may decr. seizure threshold)

• thyroid
Depacon (valproate sodium)

+

thyroid

1 interaction

Monitor/Modify Tx

valproic acid + thyroid

monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT induced)

• ticagrelor
Depacon (valproate sodium)

+

ticagrelor

1 interaction

Monitor/Modify Tx

valproic acid + ticagrelor

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• tipranavir
Depacon (valproate sodium)

+

tipranavir

1 interaction

Monitor/Modify Tx

valproic acid + tipranavir

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening; may decr. valproic acid levels, efficacy (additive effects; mechanism unknown)

• tirofiban
Depacon (valproate sodium)

+

tirofiban

1 interaction

Monitor/Modify Tx

valproic acid + tirofiban

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• tisagenlecleucel
Depacon (valproate sodium)

+

tisagenlecleucel

1 interaction

Monitor/Modify Tx

valproic acid + tisagenlecleucel

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, tisagenlecleucel may decr. seizure threshold)

• tisotumab vedotin
Depacon (valproate sodium)

+

tisotumab vedotin

1 interaction

Monitor/Modify Tx

valproic acid + tisotumab vedotin

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• tivozanib
Depacon (valproate sodium)

+

tivozanib

1 interaction

Monitor/Modify Tx

valproic acid + tivozanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• tocilizumab
Depacon (valproate sodium)

+

tocilizumab

1 interaction

Monitor/Modify Tx

valproic acid + tocilizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tofacitinib
Depacon (valproate sodium)

+

tofacitinib

1 interaction

Monitor/Modify Tx

valproic acid + tofacitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tolmetin
Depacon (valproate sodium)

+

tolmetin

1 interaction

Monitor/Modify Tx

valproic acid + tolmetin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• topotecan
Depacon (valproate sodium)

+

topotecan

1 interaction

Monitor/Modify Tx

valproic acid + topotecan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tovorafenib
Depacon (valproate sodium)

+

tovorafenib

1 interaction

Monitor/Modify Tx

valproic acid + tovorafenib

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• trabectedin
Depacon (valproate sodium)

+

trabectedin

1 interaction

Monitor/Modify Tx

valproic acid + trabectedin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tramadol
Depacon (valproate sodium)

+

tramadol

1 interaction

Monitor/Modify Tx

valproic acid + tramadol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, tramadol may decr. seizure threshold)

• trametinib
Depacon (valproate sodium)

+

trametinib

1 interaction

Monitor/Modify Tx

valproic acid + trametinib

monitor bleeding s/sx, especially w/ concomitant dabrafenib use: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• trastuzumab
Depacon (valproate sodium)

+

trastuzumab

1 interaction

Monitor/Modify Tx

valproic acid + trastuzumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• trazodone
Depacon (valproate sodium)

+

trazodone

1 interaction

Monitor/Modify Tx

valproic acid + trazodone

monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• treosulfan
Depacon (valproate sodium)

+

treosulfan

1 interaction

Monitor/Modify Tx

valproic acid + treosulfan

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, treosulfan may decr. seizure threshold)

• treprostinil
Depacon (valproate sodium)

+

treprostinil

1 interaction

Monitor/Modify Tx

valproic acid + treprostinil

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• triazolam
Depacon (valproate sodium)

+

triazolam

1 interaction

Monitor/Modify Tx

valproic acid + triazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• trifluridine
Depacon (valproate sodium)

+

trifluridine

1 interaction

Monitor/Modify Tx

valproic acid + trifluridine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• trimethoprim
Depacon (valproate sodium)

+

trimethoprim

1 interaction

Monitor/Modify Tx

valproic acid + trimethoprim

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• upadacitinib
Depacon (valproate sodium)

+

upadacitinib

1 interaction

Monitor/Modify Tx

valproic acid + upadacitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding (additive effects)

• vadadustat
Depacon (valproate sodium)

+

vadadustat

1 interaction

Monitor/Modify Tx

valproic acid + vadadustat

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding; may alter seizure control (additive effects; antagonistic effects, vadadustat may decr. seizure threshold)

• vancomycin
Depacon (valproate sodium)

+

vancomycin

1 interaction

Monitor/Modify Tx

valproic acid + vancomycin

VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

• vandetanib
Depacon (valproate sodium)

+

vandetanib

1 interaction

Monitor/Modify Tx

valproic acid + vandetanib

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• venetoclax
Depacon (valproate sodium)

+

venetoclax

1 interaction

Monitor/Modify Tx

valproic acid + venetoclax

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• venlafaxine
Depacon (valproate sodium)

+

venlafaxine

1 interaction

Monitor/Modify Tx

valproic acid + venlafaxine

monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, venlafaxine may decr. seizure threshold)

• vilazodone
Depacon (valproate sodium)

+

vilazodone

1 interaction

Monitor/Modify Tx

valproic acid + vilazodone

monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, vilazodone may decr. seizure threshold)

• vinblastine
Depacon (valproate sodium)

+

vinblastine

1 interaction

Monitor/Modify Tx

valproic acid + vinblastine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vincristine
Depacon (valproate sodium)

+

vincristine

1 interaction

Monitor/Modify Tx

valproic acid + vincristine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vinorelbine
Depacon (valproate sodium)

+

vinorelbine

1 interaction

Monitor/Modify Tx

valproic acid + vinorelbine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vinpocetine
Depacon (valproate sodium)

+

vinpocetine

1 interaction

Monitor/Modify Tx

valproic acid + vinpocetine

monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

• vorapaxar
Depacon (valproate sodium)

+

vorapaxar

1 interaction

Monitor/Modify Tx

valproic acid + vorapaxar

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• vorinostat
Depacon (valproate sodium)

+

vorinostat

1 interaction

Monitor/Modify Tx

valproic acid + vorinostat

monitor platelets: combo may incr. risk of severe thrombocytopenia, bleeding (additive effects)

• vortioxetine
Depacon (valproate sodium)

+

vortioxetine

1 interaction

Monitor/Modify Tx

valproic acid + vortioxetine

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• warfarin
Depacon (valproate sodium)

+

warfarin

1 interaction

Monitor/Modify Tx

valproic acid + warfarin

monitor INR, bleeding s/sx: combo may decr. warfarin levels, efficacy; may incr. risk of bleeding, including life-threatening (hepatic metabolism induced; synergistic effects)

• willow bark
Depacon (valproate sodium)

+

willow bark

1 interaction

Monitor/Modify Tx

valproic acid + willow bark

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects, willow bark may contain salicylates)

• zaleplon
Depacon (valproate sodium)

+

zaleplon

1 interaction

Monitor/Modify Tx

valproic acid + zaleplon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zanubrutinib
Depacon (valproate sodium)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

valproic acid + zanubrutinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

• ziconotide
Depacon (valproate sodium)

+

ziconotide

1 interaction

Monitor/Modify Tx

valproic acid + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zidovudine
Depacon (valproate sodium)

+

zidovudine

1 interaction

Monitor/Modify Tx

valproic acid + zidovudine

monitor CBC: combo may increase zidovudine levels, risk of myelosuppression, other adverse effects (UGT inhibited, additive effects)

• ziv-aflibercept
Depacon (valproate sodium)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

valproic acid + ziv-aflibercept

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• zolpidem
Depacon (valproate sodium)

+

zolpidem

1 interaction

Monitor/Modify Tx

valproic acid + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)